Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cefazolin vs cefazolin plus metronidazole for prevention of surgical site infection after hysterectomy
IRCT20200128046289N1Phase 3Completed
- Sponsor
- Babol University of Medical Sciences
- Start
- Feb 2020
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in skin and soft tissue infections (SSTIs) comparing Cefazolin prophylaxis with Cefazolin plus metronidazole prophylaxis (2 arms). Primary endpoint: Incidence of surgical site infection. Started Feb 2020; status: completed.
02
Drugs
cefazolinmetronidazole
03
Conditions
skin and soft tissue infections (SSTIs)
Beyond the preview
Go deeper on IRCT20200128046289N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200128046289N1.